The anticancer activity of alpha-tomatine against mammary adenocarcinoma in mice
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F13%3A10188907" target="_blank" >RIV/00179906:_____/13:10188907 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00216208:11150/13:10188907
Výsledek na webu
<a href="http://dx.doi.org/10.5507/bp.2013.031" target="_blank" >http://dx.doi.org/10.5507/bp.2013.031</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.5507/bp.2013.031" target="_blank" >10.5507/bp.2013.031</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
The anticancer activity of alpha-tomatine against mammary adenocarcinoma in mice
Popis výsledku v původním jazyce
Aim. To evaluate the anticancer effect of alpha-tomatine (i.p.) either alone or in combination with doxorubicin (i.v.) in a mouse tumour model. Methods. We studied the effect of repeated alpha-tomatine (0.1 - 9 mg/kg) and/or doxorubicin (2 mg/kg) on thegrowth and mitotic activity of the solid Ehrlich tumour in vivo, as well as on the survival of the tumour-bearing mice. Results. Monotherapy with alpha-tomatine had a significant dose-dependent anticancer effect which peaked at 1 mg/kg. This was shown byboth slowed tumour growth and reduced tumour cell proliferation. We also provide the first evidence that the combination alpha-tomatine (1 mg/kg) and doxorubicin (2 mg/kg) had a synergistic effect and significantly prolonged the survival of the mice. Neither alpha-tomatine nor doxorubicin influenced the infiltration of tumours with CD3+ lymphocytes; nor were we able to find an in vivo modulation of the key molecules of two regulatory pathways reported in vitro as the principal anti-canc
Název v anglickém jazyce
The anticancer activity of alpha-tomatine against mammary adenocarcinoma in mice
Popis výsledku anglicky
Aim. To evaluate the anticancer effect of alpha-tomatine (i.p.) either alone or in combination with doxorubicin (i.v.) in a mouse tumour model. Methods. We studied the effect of repeated alpha-tomatine (0.1 - 9 mg/kg) and/or doxorubicin (2 mg/kg) on thegrowth and mitotic activity of the solid Ehrlich tumour in vivo, as well as on the survival of the tumour-bearing mice. Results. Monotherapy with alpha-tomatine had a significant dose-dependent anticancer effect which peaked at 1 mg/kg. This was shown byboth slowed tumour growth and reduced tumour cell proliferation. We also provide the first evidence that the combination alpha-tomatine (1 mg/kg) and doxorubicin (2 mg/kg) had a synergistic effect and significantly prolonged the survival of the mice. Neither alpha-tomatine nor doxorubicin influenced the infiltration of tumours with CD3+ lymphocytes; nor were we able to find an in vivo modulation of the key molecules of two regulatory pathways reported in vitro as the principal anti-canc
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
CE - Biochemie
OECD FORD obor
—
Návaznosti výsledku
Projekt
<a href="/cs/project/GPP303%2F12%2FP536" target="_blank" >GPP303/12/P536: Využití tomatinu, alkaloidu z rajčat, v léčbě zhoubných nádorů</a><br>
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2013
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Biomedical Papers
ISSN
1213-8118
e-ISSN
—
Svazek periodika
157
Číslo periodika v rámci svazku
2
Stát vydavatele periodika
CZ - Česká republika
Počet stran výsledku
9
Strana od-do
153-161
Kód UT WoS článku
000321737100008
EID výsledku v databázi Scopus
—